<DOC>
	<DOCNO>NCT01604928</DOCNO>
	<brief_summary>The study intend test efficacy , safety tolerability two dos YM178 placebo tolterodine treat patient symptom active bladder .</brief_summary>
	<brief_title>Study Test Efficacy Safety YM178 Subjects With Symptoms Overactive Bladder</brief_title>
	<detailed_description>This multinational , multicenter , double-blind , double-dummy , randomize , parallel group , placebo active control phase II proof-of concept study . Patients enrol single-blind , 2-week placebo run period randomize 4 week double-blind treatment YM178 ( low dose high dose ) , placebo tolterodine . Subsequently patient follow additional 2 week single-blind placebo treatment . There 6 visit total : visit 1 enrolment , visit 2 ( baseline ) 2-week placebo run-in , visit 3 , 4 5 1 , 2 4 week double-blind treatment respectively , visit 6 2-week follow-up .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patient willing able complete micturition diary correctly . Symptoms overactive bladder ( urinary frequency urgency without incontinence ) ≥ 3 month At randomization : Patient must experience frequency micturition average ≥ 8 time per 24hour period 3day micturition diary period Patient must experience least 3 episode urgency ( grade 3 4 ) without incontinence , 3day micturition diary period Pregnant woman woman intend become pregnant study woman childbearing potential sexually active practice unreliable method birth control lactate study . Reliable contraceptive method intrauterine device , contraceptive pill combination type , hormonal implant , contraceptive patch injectable contraceptive Clinically significant outflow obstruction ( discretion investigator ) Significant post void residual volume ( PVR &gt; 200ml ) Significant stress incontinence mixed stress/urge incontinence stress predominant factor determine investigator ( female patient confirm cough provocation test ) Patients neurological cause abnormal detrusor activity Diabetic neuropathy Evidence symptomatic urinary tract infection , chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy previous current malignant disease pelvic organ Uncontrolled narrow angle glaucoma , urinary gastric retention , colitis ulcerosa , toxic megacolon , myasthenia gravis medical condition opinion investigator make use anticholinergic contraindicate Nondrug treatment include electrostimulation therapy ( bladder training program pelvic floor exercise start 1 month prior entry study continue ) Use medication intend treat urinary incontinence list Appendix 1 Part A . Part B list medication restrict accept certain condition Known suspected hypersensitivity tolterodine , anticholinergic , ßadrenoceptor agonist , lactose inactive ingredient Any clinically significant cardiovascular complication include CVA , recent myocardial infarction uncontrolled hypertension , indicate sit systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg Any clinically significant condition , opinion investigator make patient unsuitable trial Participation clinical trial within 30 ( 90 UK ) day prior randomization Employees sponsor , third party associate study , study site At randomization : Patient complete micturition diary accord instruction Average total daily urine volume &gt; 3000 ml record micturition diary Clinically significant elevation serum creatinine liver enzymes evidence creatinine &gt; 150 mmol/L , ASAT ALAT &gt; 2x upper limit normal range ( ULN ) , γGT &gt; 3x ULN and/or abnormal serum total bilirubin ( assessed visit 1 sample alternative sample within 4 week prior visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>YM178</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Frequency</keyword>
	<keyword>Urinary urge incontinence</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Micturition</keyword>
</DOC>